Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038594 | 0.90 | PTGDR2 (0.48) | KMT2AMEN1PTGDR2CCR2EDNRB | |
| SCHEMBL6038783 | 0.89 | PTGDR2 (0.48) | KMT2AMEN1PTGDR2CCR2EDNRB | |
| SCHEMBL6038924 | 0.89 | PTGDR2 (0.60) | KMT2AMEN1PTGDR2CCR2EDNRB | |
| SCHEMBL6039119 | 0.88 | PTGDR2 (0.52) | KMT2AMEN1PTGDR2CCR2EDNRB | |
| SCHEMBL6038505 | 0.87 | PTGDR2 (0.50) | KMT2AMEN1PTGDR2CCR2EDNRB | |
| SCHEMBL6039072 | 0.85 | KMT2A (0.70) | KMT2AMEN1ALDH1A1CACNA1HCACNA1B | |
| SCHEMBL6039220 | 0.82 | MEN1 (0.53) | KMT2AMEN1CCR2EDNRBEDNRA | |
| SCHEMBL6038900 | 0.82 | KMT2A (0.53) | KMT2AMEN1CCR2EDNRBEDNRA | |
| SCHEMBL6038980 | 0.77 | KDM4E (0.67) | KMT2AMEN1F2ALDH1A1MAPT | |
| SCHEMBL6038440 | 0.76 | KDM4E (0.58) | KMT2AMEN1ALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | KMT2A 4190/4885MEN1 2431/4885PTGDR2 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.